1518996-49-0
1518996-49-0
Chemical Structure
Andecaliximab
Synonym(s): Anti-MMP9 Reference Antibody (andecaliximab)
- CAS No.: 1518996-49-0
- Formula:N/A
- Molecular Weight:(150 kDa)
IUPAC Name: (E)-3-(4-hydroxyphenyl-2,3,5,6-d4)acrylic-2,3-d2 acid
SMILES: [Andecaliximab]
Biological Activity: Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Andecaliximab | 98.57% | Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Andrew E. Greenstein, et al. Effect of andecaliximab (anti-MMP9) on proteolysis of IL-7 in vitro, TCR diversity in mice, and serum IL-7 in gastric cancer patients in combination with chemotherapy. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium.
- [2]. Espindola MS, et al. Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021 Feb 15;203(4):458-470. [Content Brief]
